Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Non-Current Assets of -$330.3 million for Q4 2025, down 178.22% year-on-year from $422.2 million in Q4 2024, and down 178.22% on a QoQ basis from $422.2 million in Q4 2024.
Telix Pharmaceuticals (TLX) Non-Current Assets (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Non-Current Assets for 3 consecutive years, with -$330.3 million the latest figure, recorded in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Telix Pharmaceuticals | 3.55 Bn | 3.41 Bn | - | -330.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -330.28 Mn |
| Dec 31, 2024 | 422.23 Mn |
| Dec 31, 2023 | 122.50 Mn |